Disc Medicine, Inc. (NASDAQ:IRON) Stock Has Average Target Price of $124.18

Shares of Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $124.18.

Several equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Thursday, October 15th. Morgan Stanley raised their price objective on shares of Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a research report on Tuesday, October 20th. Wedbush lifted their price objective on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. Jefferies Financial Group reiterated a “buy” rating and issued a $149.00 target price on shares of Disc Medicine in a report on Wednesday, October 21st. Finally, Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th.

View Our Latest Analysis on IRON

Insider Buying and Selling

In related news, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the sale, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William Savage sold 16,035 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $85.09, for a total transaction of $1,364,418.15. Following the transaction, the insider directly owned 63,445 shares in the company, valued at $5,398,535.05. The trade was a 20.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 183,277 shares of company stock worth $14,489,009. Company insiders own 3.76% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors have recently modified their holdings of IRON. Aberdeen Group plc boosted its holdings in Disc Medicine by 36.4% in the third quarter. Aberdeen Group plc now owns 597,841 shares of the company’s stock worth $39,135,000 after purchasing an additional 159,667 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Disc Medicine by 142.2% during the third quarter. Russell Investments Group Ltd. now owns 19,576 shares of the company’s stock worth $1,281,000 after buying an additional 11,493 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Disc Medicine during the 3rd quarter valued at $707,000. AlphaCentric Advisors LLC raised its stake in Disc Medicine by 77.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 7,161 shares of the company’s stock valued at $469,000 after purchasing an additional 3,131 shares during the last quarter. Finally, Alps Advisors Inc. boosted its holdings in Disc Medicine by 31.9% in the 3rd quarter. Alps Advisors Inc. now owns 50,856 shares of the company’s stock valued at $3,329,000 after purchasing an additional 12,291 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Trading Down 4.4%

IRON opened at $83.23 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 20.30 and a quick ratio of 24.14. Disc Medicine has a 12-month low of $40.00 and a 12-month high of $99.50. The firm’s fifty day moving average price is $71.59 and its 200 day moving average price is $71.08. The stock has a market capitalization of $318.77 million, a PE ratio of -13.13 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, beating the consensus estimate of ($1.63) by $0.10. As a group, research analysts expect that Disc Medicine will post -6.20 EPS for the current fiscal year.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Read More

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.